Association Between RVT and Prognosis After Neoadjuvant Targeted Therapy in EGFR NSCLC
Recruiting · NCT06771960 · Observational (researchers observe without assigning treatment) · Lead sponsor: Guangdong Provincial People's Hospital
View the official record on ClinicalTrials.gov →What this trial is about
EGFR-mutated NSCLC is a distinct subtype that responds well to targeted therapies. Neoadjuvant targeted therapy aims to downstage tumors and improve surgical outcomes, but the prognostic role of residual viable tumor (RVT) remains unclear. This retrospective study examines the association between RVT and survival outcomes. The findings will further validate the importance of RVT as a surrogate.
Who can take part
Age range
18 Years to 80 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Age 18-80 years old;
- Pathologically diagnosed EGFR-mutated non-small cell lung cancer (NSCLC);
- Treated with neoadjuvant targeted therapy;
- Undergoing definitive surgery.
Exclusion criteria
- A history of prior chemotherapy, immunotherapy, or radiotherapy.
- A history of malignancy or lung surgery;
- Missing key data.
Where it is running
1 location listed.
- Guangdong Provincial People's Hospital - Guangzhou, Guangdong, China